why does tirzepatide work better than semaglutide vs. Semaglutide: Which is Best for Weight Loss? Tirzepatide vs. Semaglutide for Weight

FDA approves Ozempic to reduce the risk of kidney disease worsening, kidney failure and death due to CV disease in adults with type 2 diabetes and CKD Novo Nordisk Novo Nordisk announced that the FDA has approved Ozempic (semaglutide injection) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD)

Retatrutide itself generates significant research interest as potentially the most potent weight loss peptide developed to date, with clinical trials demonstrating unprecedented body weight reductions exceeding what semaglutide or tirzepatide achieve alone

The Adverse Events in FDAs Review Three FAERS reports were discussed FDAs briefing describes reports in its Adverse Event Reporting System involving an injection-site reaction, shortness of breath, diffuse skin darkening, and gum darkening

this phenomenon demonstrates that IR may be responsible for increased cardiovascular disease risk (70)